NASDAQ$CERS
Cerus Corp · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Total revenue grew 46% year-over-year, driven by INTERCEPT platelet uptake in the U.S., and full-year product revenue guidance was increased.
Cerus Corporation reported a strong first quarter with a 46% increase in total revenue, driven by increased sales of INTERCEPT platelet kits in the U.S. The company increased its full-year product revenue guidance from $157-164 million to $160-165 million.
- Total revenue increased by 46% year-over-year to $43.0 million.
- Product revenue increased by 60% year-over-year to $37.4 million, driven by INTERCEPT platelet kits in the U.S.
- Net loss improved by $5.2 million to $12.3 million, or $0.07 per share.
- Full-year 2022 product revenue guidance was increased to $160-165 million, representing approximately 22%-26% growth.
Headline financials
Revenue & EPS history
Cerus · Revenue · Quarterly
$37.4M
Revenue by segment
Cerus · $43M total across 2 segments · Q1 2022
- Product Revenue$37.4M+60.2%87.0%
- Government Contract Revenue$5.58M-9.9%13.0%
Forward guidance
The Company expects full-year 2022 product revenue will be in the range of $160-165 million, representing strong growth of approximately 22%-26% compared to full-year 2021 product revenue of $130.9 million.
Tailwinds
- Strong growth of approximately 22%-26% compared to full-year 2021
- Increased demand for INTERCEPT platelet kits
- Continued progress scaling up operations
- Additional manufacturing capacity coming online in 2022
- Financial discipline, resulting in operating leverage
Headwinds
- Risks associated with commercialization and market acceptance of the INTERCEPT Blood System
- Risks associated with the ultimate duration and severity of the COVID-19 pandemic
- Risks related to Fresenius Kabi’s efforts to assure an uninterrupted supply of platelet additive solution (PAS)
- Risks related to adverse market and economic conditions
- Cerus’ reliance on third parties to market, sell, distribute and maintain its products
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-0.4%
Avg return
Earnings day
+1.0%
Avg return
5 days after
-0.8%
Avg return
30 days after
48%
31 / 65 earnings
Positive
+27.5%
Q3 2017
Best reaction
-19.6%
Q1 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.7% | +34.9% | +58.3% | |
| Q4 2025 | -17.3% | -23.7% | -26.5% | |
| Q3 2025 | -2.8% | +0.0% | +21.4% | |
| Q2 2025 | +0.8% | -2.3% | +3.9% | |
| Q1 2025 | +2.3% | +0.0% | -2.3% | |
| Q4 2024 | -5.2% | -5.7% | -12.1% | |
| Q3 2024 | -7.6% | -8.2% | +8.8% | |
| Q1 2024 | -5.8% | +7.6% | +4.1% | |
| Q4 2023 | +14.2% | +6.6% | -10.8% | |
| Q3 2023 | +25.4% | +25.4% | +21.0% | |
| Q2 2023 | -17.8% | -26.3% | -35.4% | |
| Q1 2023 | -0.9% | -6.1% | -1.7% | |
| Q4 2022 | -7.0% | +2.1% | -1.4% | |
| Q3 2022 | +7.7% | +6.0% | +18.9% | |
| Q2 2022 | -4.5% | -12.7% | -32.8% | |
| Q1 2022 | +2.9% | -2.7% | -2.3% | |
| Q4 2021 | -2.1% | +8.6% | +3.6% | |
| Q3 2021 | +14.5% | +16.0% | +1.5% | |
| Q2 2021 | +21.1% | +21.9% | +28.2% | |
| Q1 2021 | +2.7% | +4.8% | -7.7% | |
| Q4 2020 | -8.6% | -3.9% | -11.3% | |
| Q3 2020 | -5.4% | -0.4% | +18.6% | |
| Q2 2020 | -1.8% | -4.7% | -17.7% | |
| Q1 2020 | +2.1% | +5.2% | +12.5% | |
| Q4 2019 | -1.0% | -6.0% | -39.2% | |
| Q3 2019 | -4.4% | -3.7% | -4.6% | |
| Q2 2019 | -8.7% | -13.5% | -8.2% | |
| Q1 2019 | -12.3% | -15.2% | -27.3% | |
| Q4 2018 | +2.8% | +6.5% | -3.7% | |
| Q3 2018 | -4.9% | -13.4% | -21.6% | |
| Q2 2018 | -5.9% | -4.8% | +4.1% | |
| Q1 2018 | +11.9% | +17.1% | +17.8% | |
| Q4 2017 | +2.1% | +7.5% | +9.0% | |
| Q3 2017 | +27.5% | +26.4% | +40.9% | |
| Q2 2017 | +3.6% | +7.1% | +6.7% | |
| Q1 2017 | -19.6% | -28.3% | -44.5% | |
| Q4 2016 | -7.8% | +5.0% | +0.7% | |
| Q3 2016 | +6.4% | +15.0% | +10.2% | |
| Q2 2016 | +1.8% | -4.5% | -11.3% | |
| Q1 2016 | -6.6% | — | — | |
| Q4 2015 | +0.5% | — | — | |
| Q3 2015 | +4.5% | — | — | |
| Q2 2015 | -2.5% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | -12.7% | — | — | |
| Q3 2014 | -5.8% | — | — | |
| Q2 2014 | +4.8% | — | — | |
| Q1 2014 | +4.4% | — | — | |
| Q4 2013 | -15.7% | — | — | |
| Q3 2013 | -6.1% | — | — | |
| Q2 2013 | +6.7% | — | — | |
| Q1 2013 | -9.7% | — | — | |
| Q4 2012 | +14.0% | — | — | |
| Q3 2012 | -1.9% | — | — | |
| Q2 2012 | -2.7% | — | — | |
| Q1 2011 | +0.5% | — | — | |
| Q1 2012 | +1.5% | — | — | |
| Q4 2009 | +0.8% | — | — | |
| Q4 2011 | +0.8% | — | — | |
| Q3 2010 | +1.4% | — | — | |
| Q3 2011 | +1.4% | — | — | |
| Q2 2010 | -2.8% | — | — | |
| Q2 2011 | -2.8% | — | — | |
| Q4 2010 | -2.8% | — | — | |
| Q1 2010 | -2.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro